TEM

The Week

Tempus AI fell 7.44% this week to $70.93, while the S&P 500 gained 1.15%, leaving the stock around 8.59 percentage points behind the benchmark. The week played out as a sharp spike and reversal. Monday opened at $76.68, pushed as high as $84.01, and closed at $83.55. Tuesday hit a weekly high of $87.99 before turning sharply lower, closing at $71.98 with intraday range exceeding 22%. The final three sessions consolidated in a lower band, ending Friday at $70.93, about 19.4% below Tuesday’s peak. Weekly amplitude came in at 27.75% on heavy volume, with daily turnover averaging roughly 9.3 million shares.

Key Events

Two threads dominated this week: the antitrust path for the Personalis acquisition and the expanded Moderna-Merck collaboration. Early in the week, the Personalis-Tempus AI deal cleared the waiting period under the HSR Act. At the same time, BTIG downgraded Personalis and said it saw no rival bid for the deal, widening the divide over deal terms and integration pressure. On Tuesday, Tempus AI fell more than 12% intraday, and some put options jumped 2300%. Later in the week, Tempus announced a multi-year collaboration with Moderna and Merck to support commercialisation of the V940 melanoma vaccine. The stock ticked higher in premarket after the news but still finished the week lower. Regulators on one side, a commercial deal on the other, moves were two-way rather than one-directional.

Analyst Ratings

As of 9 October 2026, 20 analysts cover Tempus AI, with 8 buy ratings, 2 overweight, 9 hold and 1 sell. That is 10 at buy or overweight and 1 at sell, with a consensus rating of buy. The consensus target sits at $72.72, about 2.53% above the latest price of $70.93. Target prices range from $35 to $100, a wide spread that reflects limited agreement. Within the life science tools and services industry, Tempus AI ranks 8th out of 54 companies.

The Week Ahead

Macro data dominates next week. On Tuesday 13 October, the NFIB small business optimism index and existing home sales are due. On Wednesday 14 October, CPI and core CPI land, with prior readings at 3.4% and 2.4% and forecasts at 3.7% and 2.5%. A hotter inflation print could pressure richly valued growth names further. There is no earnings event on Tempus’s calendar, so attention stays on execution of the Moderna-Merck partnership and integration progress on Personalis.

In Short

Tempus AI this week was a mix of event-driven moves and valuation sensitivity. The consensus still rates it a buy, and the target sits modestly above spot, while the Moderna-Merck deal adds commercial depth. But the price-to-book multiple is 28.6x, and the latest session shows large and medium orders as net sellers, with retail also leaning out. A near-28% weekly range, a $87.99 high and a $35 to $100 target spread point to a market still trying to find direction. The next test comes from inflation data and whether the Personalis integration creates a clearer path.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.